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Abstract
Patients with dementia frequently suffer from symptoms of agitation and
aggression. Clinicians have begun looking to alternative forms of
treatment for these symptoms in the adult population. Some researchers
have begun to look to tetrahydrocannabinol (THC) as the medical
marijuana industry continues to grow. The results from these studies
demonstrate promising efficacy with the use of THC, but there is small
evidence of a decrease in adverse events. More research is needed to
fully reach a conclusion on the clinical significance of using THC over
traditional pharmacotherapy, and to change the way clinicians currently
practice.
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Dementia is a disease that affects the brain and can cause serious deficits 
in the life of the patient and their family or caregivers. Many of the 
symptoms can take a toll on these patients, notably agitation and 
aggression. The current mainstay of treatment for these symptoms is 
atypical antipsychotics, and occasionally off-label SSRIs. Though these 
methods have shown good efficacy, the number and severity of adverse 
events that occur with these medications is concerning to patients, 
families, and providers. Due to the high side-effect profile, many 
clinicians are looking for an alternative approach with more safety and 
potentially more efficacy. Among the candidates is THC. Some preliminary 
trials have been done to evaluate the efficacy and safety of THC in these 
patients. This paper investigates the efficacy and safety of THC compared 




A literature search was conducted in November 2019 using Google 
Scholar and PubMed to find qualifying research articles to analyze. A total 
of seven articles were chosen based on publication date, recruitment 
criteria, and study design. Only studies directly studying the use of 
antipsychotics, SSRI’s like citalopram, or THC as a treatment for agitation 
and aggression were used. RCT’s were favored, but retrospective analyses 
and retrospective studies were also accepted. 
The results seen from these seven studies are 
promising. The studies somewhat lack in sample 
size and direct comparison between THC and other 
medications, but much of the data shows a lack of 
bias due to double-blinding. The recruitment 
criteria for five of the studies was marginally 
adequate, showing good inclusion criteria but room 
for improvement, where two showed adequate 
recruitment criteria. Most of the studies used 
common outcome measures like NPI-NH, CGI, 
MMSE, and number of adverse events. More 
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The Efficacy and Safety of Tetrahydrocannabinol (THC) Compared to Traditional 
Pharmacotherapy in Treating Agitation and Aggression Associated with Dementia
There is not sufficient evidence to suggest that THC 
is more effective or safer than other medications 
like atypical antipsychotics and citalopram. The 
results from these studies demonstrate promising 
efficacy with the use of THC, but there is small 
evidence of a decrease in adverse events. More 
research is needed to fully reach a conclusion on 
the clinical significance of using THC over traditional 
pharmacotherapy, including more double-blind 
RCTs with higher sample sizes. More trials directly 
comparing the two treatment methods are also 
needed to better analyze the difference in efficacy 
and safety before changing practice. 
Conclusion
Study NPI/NPI-NH CGI/CGIC MMSE AR CMAI NIQ
Herrmann et 
al
S S NS S S N/A
Van Den 
Elsen et al
NS S N/A NS NS N/A
Woodward 
et al
N/A S N/A S N/A N/A
Porsteinsson 
et al
N/A S S NS N/A N/A
Shelef et al S S S NS N/A N/A
Ahmed et al N/A N/A N/A NS N/A N/A
Teodorescu 
et al
N/A S S NS N/A S
Table 1. Comparison of Study Results
1. Herrmann N, Ruthirakuhan M, Gallagher D, et al
v RCT of 109 patients taking synthetic THC vs placebo for 
agitation/aggression. 
2. G. A. H. Van Den Elsen, Ahmed AIA, Verkes R-J, et al. 
v RCT of 54 patients taking THC vs placebo for agitation/aggression
3. Woodward MR, Harper DG, Stolyar A, Forester BP, Ellison JM. 
v Retrospective analysis of 40 patients given THC for
agitation/aggression in hospital stay.
4. Teodorescu A, Dima L, Ifteni P, Rogozea LM. 
v Retrospective analysis of 27 patients given clozapine for 
agitation/aggression.
5. Porsteinsson AP, Drye LT, Pollock BG, et al. 
v RCT of 186 patients taking citalopram vs placebo for 
agitation/aggression
6. Shelef A, Barak Y, Berger U, et al. 
v Open-label pilot study of 11 patients given synthetic THC vs 
antipsychotics for agitation/aggression
7. Ahmed AIA, Geke A. H. Van Den Elsen, Colbers A, 
v RCT of 10 patients given THC vs placebo for agitation/aggression
KEY: CMAI = Cohen-Mansfield Agitation Inventory, NPI-NH = Neuropsychiatric Inventory - Nursing Home version, 
MMSE = Mini Mental Status Exam, CGI = Clinical Global Impression scale, CGIC = Clinical Global Impression of 
Change scale, AR = Adverse Reactions, NIQ = Neuropsychiatric Inventory Questionnaire. 
S = Significant, NS = Not Significant, N/A = Not Available for this study
